TY - JOUR
T1 - NEAT1 lncRNA and amyotrophic lateral sclerosis
AU - Nishimoto, Yoshinori
AU - Nakagawa, Shinichi
AU - Okano, Hideyuki
N1 - Funding Information:
We appreciate Dr. Mari Nakamura at University of California San Diego for much support to proof the text. This work was supported by the grants JP15bm0609003, JP16bm0609003, JP17bm0609003, JP17bm0804003, JP18bm0804003, JP19bm0804003, JP20bm0804003 and JP21bm0804003 to H.O. from the Research Center Network for Realization Research Centers/Projects of Regenerative Medicine (the program for Intractable Disease Research Utilizing Disease-specific iPS Cells) in AMED and KAKENHI grants, 20H00485 to H.O. and 21K07281 to Y.N. from the Japan Society for the Promotion of Science.
Funding Information:
We appreciate Dr. Mari Nakamura at University of California San Diego for much support to proof the text. This work was supported by the grants JP15bm0609003 , JP16bm0609003 , JP17bm0609003 , JP17bm0804003 , JP18bm0804003 , JP19bm0804003 , JP20bm0804003 and JP21bm0804003 to H.O. from the Research Center Network for Realization Research Centers/Projects of Regenerative Medicine (the program for Intractable Disease Research Utilizing Disease-specific iPS Cells) in AMED and KAKENHI grants, 20H00485 to H.O. and 21K07281 to Y.N., from the Japan Society for the Promotion of Science .
Publisher Copyright:
© 2021
PY - 2021/11
Y1 - 2021/11
N2 - Amyotrophic lateral sclerosis (ALS) is a representative neurological disease that is known to devastate entire motor neurons within a period of just a few years. Discoveries of the specific pathologies of relevant RNA-binding proteins, including TAR DNA-binding protein-43 (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS), and the causative genes of both familial and sporadic ALS have provided crucial information that could lead to a cure. In recent ALS research the GGGGCC-repeat expansion in the C9orf72 gene was identified as one of the most important pathological findings, suggesting the significance of both nuclear dysfunction due to dipeptide repeat proteins (DPRs) and RNA toxicity (such as pathological alterations of non-coding RNAs). In research on model animals carrying ALS-related molecules, the determination of whether a factor is protective or toxic has been controversial. Herein, we review the findings regarding NEAT1 RNA and C9orf72 GGGGCC repeats associated with ALS, from the viewpoint of conversion from the protective stage in the nucleus in early-phase ALS to late-phase induction of cell death. This review will provide insights for the development of RNA effectors as novel ALS treatments.
AB - Amyotrophic lateral sclerosis (ALS) is a representative neurological disease that is known to devastate entire motor neurons within a period of just a few years. Discoveries of the specific pathologies of relevant RNA-binding proteins, including TAR DNA-binding protein-43 (TDP-43) and fused in sarcoma/translocated in liposarcoma (FUS/TLS), and the causative genes of both familial and sporadic ALS have provided crucial information that could lead to a cure. In recent ALS research the GGGGCC-repeat expansion in the C9orf72 gene was identified as one of the most important pathological findings, suggesting the significance of both nuclear dysfunction due to dipeptide repeat proteins (DPRs) and RNA toxicity (such as pathological alterations of non-coding RNAs). In research on model animals carrying ALS-related molecules, the determination of whether a factor is protective or toxic has been controversial. Herein, we review the findings regarding NEAT1 RNA and C9orf72 GGGGCC repeats associated with ALS, from the viewpoint of conversion from the protective stage in the nucleus in early-phase ALS to late-phase induction of cell death. This review will provide insights for the development of RNA effectors as novel ALS treatments.
KW - ALS
KW - Antisense oligonucleotide
KW - C9orf72
KW - NEAT1
KW - Nuclear body
KW - Paraspeckles
UR - http://www.scopus.com/inward/record.url?scp=85114388396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114388396&partnerID=8YFLogxK
U2 - 10.1016/j.neuint.2021.105175
DO - 10.1016/j.neuint.2021.105175
M3 - Article
C2 - 34481908
AN - SCOPUS:85114388396
SN - 0197-0186
VL - 150
JO - Neurochemistry International
JF - Neurochemistry International
M1 - 105175
ER -